Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on May 11, 2019 in Multiple Myeloma | 0 comments

In a nutshell

This study evaluated  isatuximab, pomalidomide (Imnovid) and dexamethasone (Decadron) for recurrent or non-responsive multiple myeloma (MM). This study concluded that this treatment combination was safe and effective for these patients.

Some background

There are several treatment options for patients with MM. Most initial treatments are effective. However, some patients eventually experience relapse (cancer comes back) while others develop refractory disease (cancer stops responding to treatment). These patients need alternative treatment options.

Isatuximab is a new targeted therapy which may be effective for patients with relapsed or refractory MM. This type of treatment specifically targets cancer cells. Targeted therapies are often combined with other anti-cancer drugs to enhance effectiveness. Whether isatuximab combined with pomalidomide and dexamethasone is effective and safe for relapsed or refractory MM is unclear.

Methods & findings

45 patients with relapsed or refractory MM were included in this study. Patients received an average of 3 prior lines of therapy. Patients received isatuximab, pomalidomide, and dexamethasone. Patients received treatment for an average of 9.6 months.

Overall, 62% of patients responded to treatment. On average, patients responded to treatment for an average of 18.7 months. On average, patients remained alive without tumor growth or spread for an average of 17.6 months.

Overall, all patients experienced at least 1 side effect. The most common included tiredness (62.2%) and infections in the nose, sinuses or throat (42.2%, upper respiratory tract infection). Skin reactions at the site of injection were also reported (42%). 17.8% of patients reported severe pneumonia.

Up to 98% of participants experienced decreased blood cell production. 93% of patients reported low white blood cell count. 

The bottom line

This study concluded that isatuximab combined with pomalidomide and dexamethasone was safe and effective for patients with relapsed or refractory MM.

The fine print

This was a phase 1 study. Also, this study did not include a control group. This means that there was no group to serve as a comparison for the study treatment. More studies are needed to determine the role of isatuximab in the treatment of relapsed or refractory MM.

What’s next?

If you have questions about different treatment combinations for RRMM, please consult a doctor. 

Published By :


Date :

Mar 12, 2019

Original Title :

A Phase Ib study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.

click here to get personalized updates